Overview

Moderna, Inc. is an American biotechnology and pharmaceutical company headquartered in Cambridge, Massachusetts. Its business is centered on messenger RNA, or mRNA, a biological molecule that carries instructions used by cells to make proteins. Moderna develops delivery systems and therapeutic programs intended to use synthetic mRNA to prompt cells to produce selected proteins, including antigens that can stimulate an immune response or proteins with potential therapeutic functions. The company was established in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. Stéphane Bancel became chief executive officer in 2011 and led the company through its transformation from a venture-backed research enterprise into a publicly traded vaccine and therapeutics developer. The name Moderna combines references to modified RNA and modern biotechnology. Before the COVID-19 pandemic, Moderna built a broad platform covering infectious diseases, oncology, cardiovascular and metabolic conditions, rare diseases, and other therapeutic areas. It attracted substantial venture funding and entered development and licensing relationships with companies including AstraZeneca, Alexion Pharmaceuticals, Merck, and Vertex Pharmaceuticals. The company also received support from public-sector and philanthropic organizations, including the Defense Advanced Research Projects Agency and the Bill & Melinda Gates Foundation. Moderna became widely known during the COVID-19 pandemic through its mRNA-1273 vaccine, later commercialized primarily as Spikevax. The vaccine was developed with support from the U.S. government's Operation Warp Speed program and received emergency authorization in the United States in December 2020. It subsequently received full regulatory approval for specified uses and was updated for later virus variants. COVID-19 vaccine sales made Moderna one of the most prominent commercial participants in the mRNA industry and provided resources for expanding its research, manufacturing, and international presence. The company's commercial portfolio has expanded beyond COVID-19. Its respiratory syncytial virus vaccine, mRESVIA, received U.S. Food and Drug Administration approval in 2024 for prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older. Moderna has also pursued seasonal influenza vaccines, combination respiratory vaccines, cytomegalovirus vaccination, vaccines for emerging and endemic viruses, and oncology products. Its collaboration with Merck on the personalized cancer vaccine candidate mRNA-4157/V940 has been one of its most closely watched clinical programs. Moderna has invested in manufacturing and research capacity in the United States and Canada, including a planned Canadian facility developed through an agreement involving the federal government, the province of Quebec, and McGill University. In 2023, it acquired OriCiro Genomics, a Japanese company involved in cell-free DNA production and genetic engineering tools. The acquisition was intended to strengthen aspects of Moderna's mRNA manufacturing platform. The company remains exposed to the changing post-pandemic vaccine market, clinical-development risk, regulatory review, intellectual-property disputes, and the commercial challenge of converting a successful COVID-19 product into a broader and more durable portfolio. Its strategic identity is therefore based less on a single vaccine than on an integrated mRNA platform spanning research, clinical development, manufacturing, and commercialization.

History

Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. The company was created to develop medicines based on messenger RNA, with the underlying concept that cells could be directed to produce selected proteins using synthetic genetic instructions. Stéphane Bancel became chief executive officer in 2011 and oversaw the company's development into a venture-backed biotechnology business. During its early years, Moderna raised substantial private capital and established partnerships across several medical fields. In 2013, it entered a broad collaboration with AstraZeneca covering cardiovascular, metabolic, renal, and oncology applications. It also received a DARPA grant intended to support rapidly deployable mRNA vaccines. In 2014, Moderna announced a development agreement with Alexion Pharmaceuticals and created Onkaido Therapeutics to focus on oncology. Valera Therapeutics followed in 2015 with an infectious-disease focus, while Elpidera was established to continue certain RNA programs associated with the Alexion relationship. Alexion later ended its collaboration after safety issues prevented the program from progressing to human trials. Moderna also developed partnerships with Merck in oncology and Vertex Pharmaceuticals in cystic fibrosis. The company received philanthropic support from the Bill & Melinda Gates Foundation and continued to develop vaccine candidates for influenza, Zika, cytomegalovirus, HIV, Nipah virus, chikungunya, Epstein–Barr virus, and other diseases. Its first mRNA influenza vaccine program began in 2015, while the company reported an mRNA-encoded antibody program in 2019. Manufacturing and clinical infrastructure expanded as the platform matured. In 2018, Moderna opened a large facility in Norwood, Massachusetts, for manufacturing, preclinical work, and clinical operations. That same year, it completed a Nasdaq IPO, raising approximately $621 million. The public listing gave Moderna additional capital and visibility as it advanced multiple programs that had not yet produced a commercial medicine. The company's decisive turning point came with the COVID-19 pandemic. Moderna rapidly advanced mRNA-1273, developed with support from the U.S. National Institutes of Health and other public-sector partners. The U.S. government provided substantial funding through Operation Warp Speed for development and manufacturing. The vaccine entered clinical testing in 2020 and received U.S. emergency authorization in December of that year. It was marketed as Spikevax and later received additional regulatory approvals and updated formulations. The product made Moderna a central participant in the global pandemic response and generated the company's first major commercial revenues. After the initial pandemic period, Moderna sought to use its platform and expanded manufacturing base for a larger respiratory and therapeutic portfolio. The company pursued updated COVID-19 vaccines, an RSV vaccine, seasonal influenza programs, combination respiratory vaccines, oncology candidates, and vaccines against several infectious diseases. In 2022, it announced plans for a Canadian manufacturing and research facility through a long-term partnership with the Canadian government, Quebec, and McGill University. In 2023, Moderna acquired OriCiro Genomics of Japan, its first acquisition, to strengthen genetic engineering and mRNA production capabilities. Moderna has also faced legal and strategic pressure. Arbutus Biopharma brought patent litigation concerning lipid nanoparticle technology used to deliver mRNA, and Moderna has been involved in patent disputes with Pfizer and BioNTech in multiple jurisdictions. GSK filed a separate U.S. patent action in 2024 concerning delivery technology used in Moderna's COVID-19 and RSV vaccines. At the same time, Moderna has attempted to broaden its commercial base beyond pandemic products. The FDA approval of mRESVIA in 2024 represented an important step in that effort, while the company's cancer-vaccine collaboration with Merck became a leading example of its attempt to apply mRNA to personalized oncology.

2024
mRESVIA receives FDA approval
[1]Modernaen.wikipedia.org
The company's RSV vaccine is approved in the United States for specified older-adult populations.
2023
OriCiro Genomics is acquired
[1]Modernaen.wikipedia.org
Moderna acquires the Japanese genetic engineering company in its first acquisition.
2020
COVID-19 vaccine receives U.S. emergency authorization
[1]Modernaen.wikipedia.org
Moderna's mRNA-1273 vaccine is authorized for emergency use in the United States and commercialized as Spikevax.
2018
Nasdaq initial public offering
[1]Modernaen.wikipedia.org
Moderna raises approximately $621 million in its public-market debut.
2015
Influenza and infectious-disease programs expand
[1]Modernaen.wikipedia.org
Moderna begins an mRNA influenza program and develops infectious-disease work through the Valera venture, including a Zika vaccine candidate.
2013
AstraZeneca partnership begins
[1]Modernaen.wikipedia.org
Moderna and AstraZeneca agree to collaborate on mRNA treatments in cardiovascular, metabolic, renal, and oncology areas.
2011
Stéphane Bancel becomes CEO
[1]Modernaen.wikipedia.org
Bancel takes leadership of the young biotechnology company and later guides its transition toward clinical and commercial development.
2010
Moderna is founded
[1]Modernaen.wikipedia.org
Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan establish the company to develop mRNA-based medicines.

Products and positioning

A science-led biotechnology company positioned around mRNA as a flexible platform for vaccines and therapeutics, with particular emphasis on respiratory disease, infectious disease, oncology, and scalable genetic medicine manufacturing.

COVID-19 mRNA vaccine · 2020
Spikevax
Spikevax is Moderna's principal COVID-19 vaccine brand. It uses messenger RNA encoding a SARS-CoV-2 antigen so that cells temporarily produce the antigen and stimulate an immune response. The product was initially developed as mRNA-1273, received U.S. emergency authorization in 2020, and has subsequently been updated for changing virus variants and regulatory requirements.
Respiratory syncytial virus vaccine · 2024
mRESVIA
mRESVIA is Moderna's mRNA vaccine for respiratory syncytial virus. The FDA approved it in 2024 for prevention of RSV-related lower respiratory tract disease in adults aged 60 and older. It extends Moderna's commercial respiratory portfolio beyond COVID-19 and forms part of the company's effort to establish a broader seasonal and respiratory vaccine business.
Personalized cancer vaccine candidate
mRNA-4157/V940
mRNA-4157/V940 is an individualized mRNA cancer vaccine candidate developed with Merck. The approach is designed to encode tumor-specific targets selected for an individual patient, with the aim of helping the immune system recognize and attack cancer cells. The program has received regulatory breakthrough designation and has been studied in combination with pembrolizumab.
Influenza mRNA vaccines · 2015
Seasonal influenza vaccine programs
Moderna has developed and tested mRNA-based seasonal influenza vaccine candidates. These programs seek to use the platform's design and manufacturing speed to address changing influenza strains and potentially improve the flexibility of annual vaccine production. The programs remain part of the company's broader clinical pipeline rather than a single established commercial product in the supplied reference material.

Controversies

2020
Moderna reports vaccine documents accessed in cyberattack
Moderna stated that the European Medicines Agency informed it that certain documents related to pre-submission discussions about its COVID-19 vaccine candidate had been unlawfully accessed in a cyberattack on the regulator. According to Moderna, its submission did not include information identifying individual study participants. The company disclosed the notification without providing further details on the accessed documents or the attack itself.
Source

Brand decisions

2023
Acquisition of OriCiro GenomicsM&A
Background
Moderna aimed to strengthen the tools supporting DNA production and mRNA manufacturing.
Action taken
Moderna acquired OriCiro Genomics, a Japanese genetic engineering tools company.
Aftermath
The transaction was described as Moderna's first acquisition and broadened its control over parts of the platform technology stack.
Source
2022
Canadian manufacturing and research expansionStrategy
Background
Moderna sought to build regional vaccine capacity and expand its ability to supply COVID-19 vaccines and conduct research in Canada.
Action taken
The company announced plans for a Canadian facility through a long-term partnership with the Government of Canada, Quebec, and McGill University.
Aftermath
The project became part of Moderna's international manufacturing network and its effort to support regional vaccine supply.
Planned facility investment. Approximately US$180 million announced investment (April 2022)
Source
2020
Acceleration of the mRNA-1273 COVID-19 vaccineProduct launch
Background
The COVID-19 pandemic created an urgent need for vaccines and enabled exceptional public-sector support for rapid clinical development and manufacturing.
Action taken
Moderna advanced mRNA-1273 through clinical trials with government support and brought the vaccine to emergency authorization in the United States.
Aftermath
The vaccine became the company's first major commercial product and established Moderna as a leading mRNA vaccine developer.
U.S. government support. US$955 million for development, with approximately US$4.9 billion committed in total for production of 300 million doses (2020-2021)
Source
2018
Transition to public marketsStrategy
Background
Moderna required additional capital to advance a broad portfolio of uncommercialized mRNA programs and expand manufacturing and clinical infrastructure.
Action taken
The company completed a large biotechnology initial public offering and listed on Nasdaq under the symbol MRNA.
Aftermath
The offering provided public-market financing and increased the company's visibility before its COVID-19 vaccine became commercially successful.
IPO proceeds. Approximately US$621 million raised (December 2018)
Source

Recent events

2024
Moderna's RSV vaccine mRESVIA receives U.S. approval[1]Modernaen.wikipedia.org
Product launch · Regulation
The FDA approved mRESVIA for prevention of RSV-related lower respiratory tract disease in adults aged 60 and older.
2024
GSK files patent lawsuit against Moderna[1]Modernaen.wikipedia.org
Lawsuit
GSK sued Moderna in the United States, alleging that Moderna's COVID-19 and RSV vaccines infringe patents concerning mRNA delivery technology and lipid nanoparticles.
2023
Moderna agrees to settle ownership dispute over vaccine technology[1]Modernaen.wikipedia.org
Lawsuit
Moderna agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research in connection with a dispute concerning a chemical technique used in its COVID-19 vaccine.
2020
Moderna's COVID-19 vaccine receives U.S. emergency authorization[1]Modernaen.wikipedia.org
Product launch · Regulation
The mRNA-1273 COVID-19 vaccine received emergency authorization in the United States, establishing Moderna as a major commercial vaccine developer.
2018
Moderna becomes a public company[1]Modernaen.wikipedia.org
Other
Moderna completed an initial public offering on Nasdaq, raising approximately $621 million and becoming one of the largest biotechnology IPOs at that time.